Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Financing Activities (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Cash from Financing Activities for 15 consecutive years, with -$122214.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 1885.97% year-over-year to -$122214.0, compared with a TTM value of -$214633.0 through Sep 2025, down 521.44%, and an annual FY2024 reading of $27353.0, down 62.6% over the prior year.
  • Cash from Financing Activities was -$122214.0 for Q3 2025 at China Pharma Holdings, down from -$29188.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $4.6 million in Q4 2021 and bottomed at -$850555.0 in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $142462.8, with a median of $934.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities surged 45928.53% in 2021, then tumbled 1885.97% in 2025.
  • Year by year, Cash from Financing Activities stood at $4.6 million in 2021, then tumbled by 114.55% to -$672063.0 in 2022, then soared by 104.52% to $30378.0 in 2023, then crashed by 77.61% to $6802.0 in 2024, then crashed by 1896.74% to -$122214.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for CPHI at -$122214.0 in Q3 2025, -$29188.0 in Q2 2025, and -$70033.0 in Q1 2025.